John Hohneker

2.4k total citations
40 papers, 1.9k citations indexed

About

John Hohneker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, John Hohneker has authored 40 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in John Hohneker's work include Cancer Treatment and Pharmacology (20 papers), Colorectal Cancer Treatments and Studies (16 papers) and Pancreatic and Hepatic Oncology Research (5 papers). John Hohneker is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), Colorectal Cancer Treatments and Studies (16 papers) and Pancreatic and Hepatic Oncology Research (5 papers). John Hohneker collaborates with scholars based in United States, Switzerland and Canada. John Hohneker's co-authors include Laura F. Hutchins, Joseph Bigley, Leo V. Lacerna, Edith A. Perez, Adam Brufsky, J. Thaddeus Beck, W G Harker, C. W. Seidler, Stephen E. Jones and Mark Allen O’Rourke and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

John Hohneker

40 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Hohneker United States	23	1.5k	496	290	278	263	40	1.9k
Erhard Quebe‐Fehling Switzerland	15	1.2k 0.8×	393 0.8×	228 0.8×	212 0.8×	614 2.3×	42	1.9k
N. Davidson United Kingdom	15	1.3k 0.9×	357 0.7×	358 1.2×	181 0.7×	270 1.0×	41	1.9k
Paola Papaldo Italy	25	1.1k 0.8×	336 0.7×	411 1.4×	48 0.2×	439 1.7×	66	1.7k
Yang Yao China	29	1.2k 0.8×	1.1k 2.2×	694 2.4×	180 0.6×	302 1.1×	125	2.4k
RD Rubens United Kingdom	16	1.3k 0.9×	419 0.8×	316 1.1×	141 0.5×	258 1.0×	16	1.7k
G. Gorzegno Italy	21	836 0.6×	440 0.9×	249 0.9×	99 0.4×	249 0.9×	51	1.4k
Ted Vandenberg Canada	19	1.4k 1.0×	585 1.2×	381 1.3×	54 0.2×	761 2.9×	39	2.0k
P Soulié France	25	1.7k 1.1×	761 1.5×	369 1.3×	46 0.2×	394 1.5×	118	2.3k
Blair Egerdie Canada	15	916 0.6×	712 1.4×	306 1.1×	407 1.5×	115 0.4×	31	1.7k
Michela Donadio Italy	23	1.1k 0.7×	330 0.7×	352 1.2×	128 0.5×	543 2.1×	68	1.8k

Countries citing papers authored by John Hohneker

Since Specialization

Citations

This map shows the geographic impact of John Hohneker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Hohneker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Hohneker more than expected).

Fields of papers citing papers by John Hohneker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Hohneker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Hohneker. The network helps show where John Hohneker may publish in the future.

Co-authorship network of co-authors of John Hohneker

This figure shows the co-authorship network connecting the top 25 collaborators of John Hohneker. A scholar is included among the top collaborators of John Hohneker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Hohneker. John Hohneker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

LoRusso, Patricia, Renzo Canetta, John A. Wagner, et al.. (2012). Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop. Clinical Cancer Research. 18(22). 6101–6109. 42 indexed citations

Brufsky, Adam, W G Harker, J. Thaddeus Beck, et al.. (2011). Final 5‐year results of Z‐FAST trial. Cancer. 118(5). 1192–1201. 148 indexed citations

Weitzman, Richard E., Nicholas Sauter, Erik Fink Eriksen, et al.. (2007). Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Critical Reviews in Oncology/Hematology. 62(2). 148–152. 146 indexed citations

Brufsky, Adam, W G Harker, J. Thaddeus Beck, et al.. (2006). Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer. Journal of Clinical Oncology. 25(7). 829–836. 236 indexed citations

Rothermel, J. D., Markus Wartmann, Tse‐Ching Chen, & John Hohneker. (2003). EPO906 (epothilone B): A promising novel microtubule stabilizer. Seminars in Oncology. 30(3). 51–55. 46 indexed citations

Rothermel, J. D., Markus Wartmann, Tianling Chen, & John Hohneker. (2003). EPO906 (epothilone B): A promising novel microtubule stabilizer. Seminars in Oncology. 30(3 Suppl 6). 51–55. 32 indexed citations

Benson, Al B., Edith P. Mitchell, Neil Abramson, et al.. (2002). Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Annals of Oncology. 13(4). 576–581. 12 indexed citations

Levin, Jeremey & John Hohneker. (2000). Clinical Development of Eniluracil/Fluorouracil: an Oral Treatment for Patients with Solid Tumors. Investigational New Drugs. 18(4). 383–390. 6 indexed citations

Havlin, Kathleen A., et al.. (1999). Inability to escalate vinorelbine dose intensity using a daily × 3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 43(1). 68–72. 3 indexed citations

10.

Gershenson, David M., et al.. (1998). A Phase I Study of a Daily ×3 Schedule of Intravenous Vinorelbine for Refractory Epithelial Ovarian Cancer. Gynecologic Oncology. 70(3). 404–409. 33 indexed citations

11.

Schilsky, Richard L., John Hohneker, Mark J. Ratain, et al.. (1998). Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.. Journal of Clinical Oncology. 16(4). 1450–1457. 91 indexed citations

12.

Peacock, N. W., H.A. Burris, Véronique Dièras, et al.. (1998). A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Investigational New Drugs. 16(1). 37–43. 5 indexed citations

13.

New, Pamela, et al.. (1997). Long-term response to crisnatol mesylate in patients with glioma.. Investigational New Drugs. 15(4). 343–352. 6 indexed citations

14.

Rowinsky, Eric K., Virginie Lucas, William A. Wargin, et al.. (1996). The effects of food and divided dosing on the bioavailability of oral vinorelbine. Cancer Chemotherapy and Pharmacology. 39(1-2). 9–16. 11 indexed citations

15.

Crawford, Jeffrey, Mark Allen O’Rourke, Joan H. Schiller, et al.. (1996). Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.. Journal of Clinical Oncology. 14(10). 2774–2784. 100 indexed citations

16.

Baker, Sharyn D., S P Khor, Alex A. Adjei, et al.. (1996). Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.. Journal of Clinical Oncology. 14(12). 3085–3096. 117 indexed citations

17.

Vokes, Everett E., Richard K. Rosenberg, Mohammad Jahanzeb, et al.. (1995). Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer.. Journal of Clinical Oncology. 13(3). 637–644. 34 indexed citations

18.

Rowinsky, Eric K., D A Noe, D L Trump, et al.. (1994). Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.. Journal of Clinical Oncology. 12(9). 1754–1763. 52 indexed citations

19.

Schilsky, Richard L., Mark J. Ratain, Linda Janisch, et al.. (1993). Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemotherapy and Pharmacology. 31(4). 283–288. 1 indexed citations

20.

Hohneker, John, et al.. (1982). Saponification of dimethyl cis-2,6-diphenyl-4-oxocyclohexane-1,1-dicarboxylate. A reinvestigation. The Journal of Organic Chemistry. 47(2). 301–306. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact